To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD). Methods: The authors conducted a hypothesis-generating, exploratory analysis of a 24-week, double-blind, placebocontrolled trial comparing memantine (20 mg/day) with placebo in subjects with moderate to severe AD on stable donepezil treatment. They employed the Neuropsychiatric Inventory (NPI; 12-item), administered at baseline, week 12, and week 24, to assess the effects of memantine on behavior. Global, cognitive, and functional measures were collected and relationships between these assessments and changes in behavior were determined. The intent-to-treat population was examined using last-observation-carried-forward and observed-cases approaches. Results: Patients treated with memantine had significantly lower NPI total scores than patients treated with placebo. Analyses of the 12 NPI domains revealed significant effects in favor of memantine on agitation/aggression, eating/appetite, and irritability/lability. Of patients who exhibited agitation/aggression at baseline, those treated with memantine showed significant reduction of symptoms compared with placebo-treated patients. Memantine-treated patients without agitation/aggression at baseline evidenced significantly less emergence of this symptom compared with similar patients receiving placebo. Caregivers of patients receiving memantine registered significantly less agitation-related distress. There were significant relationships between the NPI and the global rating scale and performance of activities of daily living, but not between changes in the NPI and cognition. Conclusion: Treatment with memantine reduced agitation/aggression, irritability, and appetite/eating disturbances. Memantine reduced agitation/aggression in patients who were agitated at baseline and delayed its emergence in those who were free of agitation at baseline.
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Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist that has shown efficacy in improving cognition and function relative to placebo in the treatment of moderate to severe Alzheimer disease (AD). 1, 2 Agents that improve cognitive and functional performance in dementia often have effects on behavior as well. For example, reduced behavioral abnormalities have been shown in clinical trials of ␣-tocopherol plus selegiline 3 and cholinesterase inhibitors. 4 The potential behavioral effects of memantine have not been studied thoroughly.
We conducted a hypothesis-generating, post-hoc analysis of behavioral observations collected in a clinical trial in patients already receiving a stable dose of the cholinesterase inhibitor donepezil and randomized to memantine or placebo. 1 In this trial, patients treated with memantine showed overall behavioral improvement based on the total score from the Neuropsychiatric Inventory (NPI). 5 We wished to explore this behavioral response in more detail. Specifically, we examined whether memantine produced a reduction in frontally mediated behaviors including agitation, irritability, disinhibition, and euphoria, predicting that frontally mediated behaviors would be preferentially affected. We also investigated the relationship between behavioral outcomes of the trial and the impact of memantine treatment on global function, activities of daily living (ADL), and cognition. In previous studies, relationships between changes in behavior and ADL have been more
Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the July 11 issue to find the title link for this article.
marked than correlations between behavioral alterations and changes in cognition. [6] [7] [8] [9] [10] We predicted that similar results would emerge from this study.
In trials of antidementia agents, patients are not selected for specific behavioral disturbances at baseline, and the entry population includes patients who exhibit behavioral changes and patients who are asymptomatic for some behaviors. Patients who are symptomatic at baseline may experience a reduction, increase, or no change in their behavioral symptoms in the course of the trial. Patients who are asymptomatic at baseline may continue to be asymptomatic or may manifest the emergence of new behaviors in the course of the trial. In the latter, reduced emergence of new behaviors in the treatment group compared with the placebo group is evidence for a behavioral benefit. Likewise, reduction or no change in behaviors compared with worsening of behaviors in a placebo group of patients with symptoms at baseline is evidence of a behavioral response to therapy. Thus, we also conducted analyses addressing patients who evidenced behavioral symptoms at baseline and patients who were behaviorally asymptomatic at baseline.
Methods.
Participants. The methodology of this clinical trial (Study MEM-MD-02) has been reported previously.
1 Participants included 404 patients from 37 sites in the United States with a diagnosis of probable AD according to the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria. 11 Patients had a Mini-Mental State Examination (MMSE) score 12 of 5 to 14 at both screening and baseline, were at least 50 years of age, had MRI or a CT scan within the previous 12 months consistent with a diagnosis of AD, were receiving ongoing therapy with the cholinesterase inhibitor donepezil for at least 6 months and had been on a stable dose (5 or 10 mg/day) for at least 3 months, had a knowledgeable caregiver who could provide health-related information, were residents in the community, were ambulatory or ambulatory assisted (i.e., walker or cane), and were stable medically. Patients were allowed to enter the trial if they were receiving stable doses of medications including psychotropics (i.e., antidepressants, antipsychotics, and sedative hypnotics).
Patients were excluded because of vitamin B 12 or folate deficiency, active systemic illness, or a history of psychiatric or CNS disorder other than AD. A modified Hachinski Ischemia Scale score 13 of greater than 4 also excluded the patient from participation.
Written informed consent was obtained from the caregiver and either the patient (where possible) or the patient's surrogate. The study was reviewed and approved by the institutional review board of each participating site.
Interventions. The study was a prospective, randomized, placebo-controlled, parallel-group, fixed-dose trial in which participants were assigned to treatment for 24 weeks after a 1-to 2-week single-blind placebo lead-in period. Patients were randomly allocated to one of the two treatment blocks in permuted blocks of four in accordance with the randomization list generated and retained by the Department of Biostatistics at Forest Laboratories.
Patients assigned to double-blind memantine treatment were titrated in 5-mg weekly increments from a starting dose of 5 to 20 mg/day administered as 2 5-mg tablets twice daily at the beginning of week 4. Drug and placebo tablets were visually identical, and all patients received 4 tablets of study medications daily. Patients were maintained on stable donepezil therapy throughout the course of the study.
Outcome measures. Behavioral, cognitive, functional, and global outcome measures were obtained in the course of the study. 1 Cognitive, ADL, and global measures were collected at baseline and at the end of weeks 4, 8, 12, 18, and 24. Behavioral measures were obtained at baseline, at the end of week 12, and at week 24. The primary efficacy measures were the change from baseline on the Severe Impairment Battery (SIB) 14 Secondary outcomes of the study included the NPI, 5 the Clinician's Interview-Based Impression of Change with Caregiver Input (CIBIC-Plus; ADCS version), 17 and the Behavioral Rating Scale for Geriatric Patients (BGP). 18 The CIBIC-Plus incorporates both observer and caregiver information and is rated on a scale from 1 (marked improvement) to 7 (marked worsening), with a score of 4 indicating no change. The BGP consists of 35 items assessing observable aspects of cognition, function, behavior, and dependence on the caregiver. Lower scores on the BGP indicate more intact function.
The NPI assesses behaviors common in dementia including delusions, hallucinations, agitation/aggression, dysphoria/depression, anxiety, euphoria, disinhibition, irritability, aberrant motor behavior, alterations in appetite, apathy, and changes in nighttime behavior. The scores are based on interviews with caregivers and assess behaviors that were present in the last 4 weeks. Frequency and severity scores are elicited from the caregiver with anchored ratings, and the total score for each domain is the product of the severity score (1 to 3) multiplied by the frequency score (1 to 4). The total score for the NPI is the sum of the individual domain scores, ranging from 0 to 144. The NPI also includes a caregiver distress rating. Caregivers rate their own distress associated with each behavior on an anchored scale of 0 to 5. The total NPI distress score is the sum of the distress scores associated with each behavioral domain and can range from 0 to 60. For both scales, higher scores reflect worse symptoms or distress. Every effort was made to insure that patient informants for interviewbased instruments (NPI, ADCS, ADL 19 , CIBIC-Plus) were the same throughout the study.
Sample size and statistical analyses. The sample size was based on a hypothetical effect size of 0.35 on the primary outcomes and required a sample of at least 170 patients in each treatment group to provide 90% power at a two-sided ␣ level of 0.05.
All randomly assigned patients who received at least 1 dose of study medication were included in the analysis of data on safety, demographic variables, and baseline characteristics (n ϭ 403). All efficacy analyses were derived from the modified intent-to-treat population (n ϭ 395), which included those randomized subjects who completed at least one postbaseline assessment of the primary efficacy measure.
For this report, analyses were produced using both observedcases (OC) and last-observation-carried-forward (LOCF) approaches. Although for the sake of brevity only LOCF analyses are reported, few discrepancies between approaches were noted. Results of the parametric analyses using a two-way analysis of covariance (ANCOVA) model with treatment group and center as effects and the baseline score as a covariate are reported. For comparing proportions of responders between the two treatment groups, a 2 test was used. As these analyses are for the purposes of hypothesis generation, all between-group comparisons were made at the 5% level of significance with no adjustments for multiple comparisons.
The first set of analyses examined the effects of memantine treatment on the total scores and individual NPI domain scores. Next, the effects of memantine on emergence of new behavioral symptoms and on suppression of existing behavioral dysfunction in patients with moderate to severe AD were assessed. This was followed by assessment of memantine's influence on caregiver distress. The stability of behavioral benefit conferred by treatment over time was determined by examining the proportion of patients treated with memantine who were defined as "responders" (total NPI score unchanged or less at week 12 or 24 visits relative to baseline) at weeks 12 and 24. Last, correlation analyses examined the relationships among variables (NPI total score, caregiver's distress score, CIBIC-Plus, SIB total score, and ADCS-ADL 19 total score) with respect to time (week 12 and 24 visit).
Results. Participants. Four hundred four patients were enrolled in the study; 201 were randomized to placebo, and 203 were randomized to memantine treatment (1 patient in the memantine group withdrew consent before receiving treatment and was excluded from the safety and baseline demographic analyses). Adherence to the study protocol was assessed by returned tablets, and over 95% of the study group had compliance of 75% or better; patients were excluded for lack of compliance. Eighty-five percent of the participants in the memantine group completed the study, and 74.6% of patients in the placebo group completed all evaluations. Table 1 shows the baseline characteristics of the study population. Thirty-three percent of the placebo group and 37% of the memantine group were men; average age for both groups was 75.5, and most patients were white (92.5% of the placebo group, 90.1% of the memantine group). Mean baseline MMSE scores were 10.2 in the placebo and 9.9 in the memantine group, indicating that patients had moderate to severe dementia. Overall, there were no significant imbalances between the treatment groups in demographic and baseline clinical characteristics.
Mean baseline NPI scores of 13.8 for the placebo group and 13.7 for the memantine group indicate that most patients in the trial had low to moderate levels of psychopathology at entry. The highest scores recorded were for apathy, aberrant motor behavior, agitation, anxiety, irritability, nighttime behavioral disturbances, and appetite/ eating changes. The two groups were well matched with respect to concomitant use of psychotropic medications.
NPI total and domains at weeks 12 and 24. The leastsquares (LS) mean total NPI score increased (worsening behavior) by 1.7 points (SD 11.9) in the placebo group and declined (improved behavior) by 2.5 points (SD 11.0) in the memantine group at week 12 (p Ͻ 0.001; LOCF). At week 24, the placebo group continued to deteriorate behaviorally with an LS mean total NPI change score of 3.7 (SD 14.0), whereas the memantine group returned approximately to baseline (p ϭ 0.002). Observed cases analyses gave similar results (table 2; figure 1) .
With use of LOCF data, the LS mean memantineplacebo difference at week 12 was 4.2 points, and at week 24 it was 3.8 points. With use of the OC approach, the LS mean difference at week 12 was 4.4 points and at week 24 3.4 points. With baseline scores of 13.7 in the memantine treatment group, the 3.8-and 3.4-point drug-placebo difference at week 24 represents a 28 to 25% reduction.
Analyses of the domains of the NPI revealed significant differences at week 12 for agitation, irritability, and appetite/eating changes (ANCOVA; LOCF). At week 24, there were significant differences in favor of memantine on the same items. No behaviors worsened significantly on memantine compared with placebo (figure 2; see also figure E-1 on the Neurology Web site; go to www.neurology.org). OC analysis gave similar results.
Among patients with no behavioral symptoms in specific domains at baseline, fewer patients treated with memantine exhibited emergence of delusions (94 vs 85% remained asymptomatic in memantine and placebo groups, p ϭ 0.011; LOCF) and agitation (89 vs 79%, p ϭ 0.032; LOCF) at week 12 when compared with those receiving placebo. At week 24, fewer patients treated with memantine evidenced the emergence of agitation (85 vs 73% remained asymptomatic in memantine and placebo groups, p ϭ 0.016; LOCF), irritability (88 vs 78%, p ϭ 0.041; LOCF), and nighttime behavior (89 vs 80%, p ϭ 0.027; LOCF) (figure 3). OC analyses gave similar results. There were no behavioral domains in which there was greater emergence of maladaptive behavioral changes in the memantine group compared with the placebo group.
Patients who exhibited specific symptoms at baseline also were analyzed. At week 12, there were lower scores in the group receiving memantine on agitation (LS mean difference between memantine and placebo [95% CI]: Ϫ1.2 [Ϫ2.2, Ϫ0.2], p ϭ 0.018; ANCOVA, LOCF) and appetite Anxiolytics/hypnotics 14 (7.9) 16 (7.9) * Numbers of patients differed between the baseline evaluation and those reported for all efficacy analyses, including the NPI analyses; baseline included all patients randomized; NPI analyses included all patients who had at least one postrandomization assessment (modified intent-to-treat subset). † n ϭ 196 for the placebo group as one patient had an incomplete BGP baseline assessment and was not included. Stability of behavioral response. An analysis of therapeutic benefits of memantine treatment was carried out to determine the stability of behavioral responses over time. Defining a responder as an individual with a reduction of 1 point or greater below baseline on the total NPI score at the specified measurement times (week 12 or 24), the majority (84%) of those who responded to memantine treatment at week 24 also had a positive response at week 12; a similar pattern was observed in patients receiving placebo. Of the total number of patients who responded in this study (at either time point), 65% demonstrated a response at both time points. A greater proportion of patients treated with memantine compared with those on placebo achieved a positive behavioral response at the midpoint (week 12) and end (week 24) of the study (50 vs 37%, p ϭ 0.005; 2 test, df ϭ 1). Caregiver Distress Scale. When the total Caregiver Distress Scale scores were considered, there were differ- Relationships between behavioral measures and other outcomes. As shown in table 3, there were significant correlations between the change in NPI total score and the CIBICPlus and between the change in NPI total score and change in ADCS-ADL 19 total score for both placebo and memantine groups in both the LOCF and OC analyses. In the LOCF analysis, the change in NPI total score accounted for approximately 20% of the changes in the CIBIC-Plus. As expected, there were marked correlations between the NPI total scores and the total caregiver distress scores on all analyses. Significant relationships also existed between the CIBIC-Plus and the NPI Caregiver Distress Scale (stronger in the LOCF analyses than the OC analyses). As hypothesized, no correlation was seen in the analyses between the NPI total score and cognition as measured by the SIB.
Safety and tolerability. The safety and tolerability of memantine for patients in this trial have been reported previously. Discussion. This exploratory analysis of the NPI included as a secondary outcome measure of a randomized, placebo-controlled trial suggests that memantine has behavioral benefits in addition to the favorable impact on cognition and function evidenced on primary outcome measures. We observed significant and consistent changes on agitation/aggressiveness in all analyses (weeks 12 and 24; LOCF and OC). In patients who were not agitated at baseline, there was significantly less emergence of agitation/ aggressiveness at weeks 12 and 24, and in patients symptomatic at baseline, there was significantly less worsening of agitation at weeks 12 and 24. Caregivers of patients receiving memantine registered significantly less distress at week 24 for the agitation/ aggressiveness item compared with caregivers of those receiving placebo. In addition, we observed similar patterns in responses to memantine therapy on the irritability, nighttime behavior disturbances, and eating changes items. No neuropsychiatric symptoms recorded on the NPI increased in memantine patients compared with patients receiving placebo. The consistency and magnitude of the results support the hypothesis that memantine reduces agitation/aggressiveness, irritability, and appetite and eating changes in patients with AD. Thus, the results of this post-hoc analysis partially support our first hypothesis that memantine would have preferential effects on frontally mediated behavioral disturbances. Examination of the relationship between changes in NPI scores and those of other outcome measures supported our second hypothesis. We observed significant relationships between the NPI and the CIBIC-Plus and between the NPI and the ADCS-ADL 19 scales. We did not observe relationships between the NPI and cognitive outcomes as measured by the SIB. These results are consistent with observations from other studies suggesting that cognitive and behavioral changes in AD have different pathophysiologic bases and respond differentially to therapeutic interventions. ADL and behavior are dependent on frontal lobe function 6, 19 and often are correlated. The relevance of a 4-point NPI difference between memantine-treated and placebo-treated patients is reflected by the patterns of responses seen on the NPI Caregiver Distress Scale. Caregivers of patients receiving memantine had significantly less distress at week 24 for agitation/aggression, nighttime behavior, and eating changes. Agitation/aggression is the NPI variable most closely linked to caregiver quality of life. Patients with AD and behavioral alterations produce higher care costs than patients with fewer behavioral changes. A 1-point increase on the NPI was calculated to be equivalent to an increased cost of $247 to $409 in total annual direct costs. 21 Thus, the approximately 4-point NPI difference between drug and placebo groups observed in this study would translate into substantial cost savings.
All patients included in this trial were on the cholinesterase inhibitor donepezil, and previous studies indicate that cholinesterase inhibitors reduce behavioral abnormalities in patients with AD. 4, 7, 19, [22] [23] [24] [25] [26] [27] [28] [29] [30] In the current trial, all patients had been on donepezil for at least 6 months, and the mean treatment duration was more than 2 years. The behavioral effects presented occurred in those randomized to donepezil plus memantine and not those on donepezil plus placebo. This suggests that the behavioral benefits observed in the current study were attributable to memantine; an interaction between memantine and donepezil cannot be excluded.
The mechanism by which memantine exerts a psychotropic effect is uncertain. Memantine is an uncompetitive NMDA receptor antagonist with rapid voltage-dependent blocking/unblocking kinetics. 31 It is hypothesized that memantine blocks the excitotoxicity associated with chronic low-level glutamate stimulation. 32 The accumulation of amyloid ␤-protein (A␤) is increasingly regarded as the central event in the etiopathogenesis of AD, 33 and A␤ toxicity is mediated at least in part by a glutamate-triggered excitotoxic cascade. 34 Glutamate excitotoxicity has been associated with the tau hyperphosphorylation required in the production of neurofibrillary tangles and regarded as an important executioner pathway in AD. 35 Neurofibrillary tangles have been linked to frontal lobe dysfunction and agitation. 6, 36, 37 This putative relationship between glutamate toxicity and abnormalities of tau metabolism led to our hypothesis that memantine would have a disproportionate effect on frontally mediated behaviors.
This study has several limitations, and caution must be exercised in generalizing the results. This is a post-hoc exploratory analysis of a secondary outcome, and the results must be confirmed in prospective clinical investigations. No effort was made to correct for repeated statistical testing. Patients were not selected on the basis of specific behavioral abnormalities, and most patients exhibited relatively few behavioral changes at baseline, as reflected by the relatively low baseline NPI scores. The effect of memantine on patients with more severe behavioral disturbances is uncertain. All patients in this study were on donepezil, which is known to exhibit behavioral effects, 4 and some patients were on psychotropic medications. The behavioral effects reported here were evident in the memantine plus donepezil and not in the placebo plus donepezil group. The randomization process produced approximately equal numbers of patients on psychotropics in the placebo and memantine groups, but the potential interaction of psychotropic medications, donepezil, and memantine in producing the observed behavioral responses is not known.
